Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant

Open Forum Infectious Diseases

Volumn 1, Issue 3, 2014, Pages

  Chen, Wilbur H ^a   Jackson, Lisa A ^b   Edwards, Kathryn M ^c   Keitel, Wendy A ^d   Hill, Heather ^e   Noah, Diana L ^f   Creech, C Buddy ^c   Patel, Shital M ^d   Mangal, Brian ^e   Kotloff, Karen L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e EMMES CORPORATION   (United States)

^f SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvants; Avian influenza; Pandemic influenza vaccine

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; VIRUS VACCINE;

ABDOMINAL PAIN; ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; ESOPHAGITIS; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H5N1); INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NAUSEA; NECK PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION;

EID: 84978328521     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu091     Document Type: Article

References (25)

1. Jennings LC, Monto AS, Chan PK, et al. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis. 2008;8:650-58.
2. Belshe RB, Frey SE, Graham I, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis. 2011;203:666-73.
3. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354:1343-51.
4. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine. 2001;19:1732-37.
5. Noah DL, Hill H, Hines D, et al. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol. 2009;16:558-66.
6. Chen WH, Winokur PL, Edwards KM, et al. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine. 2012;30:4240-48.
7. Atmar RL, KeitelWA. Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol. 2009;333:323-44.
8. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006;367:1657-64.
9. KeitelWA, Campbell JD, Treanor JJ, et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis. 2008;198:1309-16.
10. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007; 370:580-9.
11. Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis. 2010;201:1644-53.
12. Department of Health and Human Services . HHS funds the advanced development of vaccines against the H5N1 influenza strain, 2007. http://www.globalhealth.gov/news-and-events/archive-news/2007/20070119-hhs.html. Accessed January 23, 2014.
13. Dekker CL, Gordon L, Klein J; for the NVAC Subcommittee on Vaccine Development and Supply. Dose optimization strategies for vaccines: the role of adjuvants and new technologies, 2008. http://www.hhs.gov/nvpo/nvac/reports/index.html. Accessed January 23, 2014.
14. Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature. 2006;442:448-52.
15. Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Rockville, MD: Department of Health and Human Services, 2007. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074786.htm. Accessed January 23, 2014.
16. Schwarz TF, Horacek T, Knuf M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine. 2009;27:6284-90.
17. Gilca V, De Serres G, Hamelin ME, et al. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine. 2011;30:35-41.
18. Sridhar S, Begom S, Bermingham A, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013;19:1305-12.
19. WHO/OIE/FAO H5N1 Evolution Working Group. Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza Other Respir Viruses. 2012;6:1-5.
20. Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis. 2011; 203:1729-38.
21. Lasko B, Reich D, Madan A, et al. Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults. J Infect Dis. 2011;204:574-81.
22. Yang PC, Yu CJ, Chang SC, et al. Safety and immunogenicity of a splitvirion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults. J Formos Med Assoc. 2012;111:333-9.
23. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37:937-43.
24. Baylor NW, Houn F. Considerations for licensure of influenza vaccines with pandemic and prepandemic indications. Curr Top Microbiol Immunol. 2009;333:453-70.
25. De la Herran-Arita AK, Kornum BR, Mahlios J, et al. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med. 2013;5:216ra176.